We take a look at what personalised cancer vaccines are, how they are developed, and how they are changing the field of immunotherapy.

Antisense oligonucleotides hold major promise in future patient treatment approaches. Through targeting RNA to regulate protein expression, they can help to address diseases at their source and advance therapeutic outcomes.

Here, we outline some of the main trends anticipated in market growth and development for biologics in the next few years. The global biologics market is predicted to exceed $600bn by 2032, driven by demand for personalised treatments for chronic diseases.

How are oligo therapeutics revolutionising genetic disease treatments through precise targeting and transformative therapies? In this article, we explore how they provide precise gene expression interference for untreatable conditions by directly targeting disease-associated proteins and genetic mutations.

We take a look at how the commercialisation of COVID-19 vaccines in the US will impact the price of the vital therapeutic.

The Pharma giants have partnered to advance the development of bispecific T cell engaging antibodies using WuXi’s platforms.